Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

Albireo Pharma logo

About Albireo Pharma Stock (NASDAQ:ALBO)

Advanced Chart

Key Stats

Today's Range
$43.99
$44.90
50-Day Range
$43.50
$44.95
52-Week Range
$16.02
$45.23
Volume
1.24 million shs
Average Volume
704,539 shs
Market Capitalization
$913.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALBO Stock News Headlines

Prospect Park II in Fort Lauderdale
Tax Drain Deadline: Protect Your Wealth Before September 15th
On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained.tc pixel
ALBO Historical Data
ALBO Albireo Pharma, Inc.
Albireo Pharma, Inc. (ALBO)
See More Headlines

ALBO Stock Analysis - Frequently Asked Questions

Albireo Pharma, Inc. (NASDAQ:ALBO) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 EPS for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company had revenue of $3.66 million for the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Albireo Pharma investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW) and Devon Energy (DVN).

Company Calendar

Last Earnings
11/04/2021
Today
8/28/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALBO
CIK
1322505
Employees
130
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
($6.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.03 million
Net Margins
-228.51%
Pretax Margin
-235.11%
Return on Equity
-97.13%
Return on Assets
-46.89%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.32
Quick Ratio
6.23

Sales & Book Value

Annual Sales
$40.58 million
Price / Sales
22.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.11 per share
Price / Book
4.85

Miscellaneous

Outstanding Shares
20,700,000
Free Float
19,273,000
Market Cap
$913.91 million
Optionable
Optionable
Beta
1.03

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:ALBO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners